Ronit Satchi-Fainaro

CIK: 0001742782

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)2 (40.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Aug 21, 2026
Sale(S)
Direct
415 shares at avg. $37.25$15K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Jun 5, 2026
Exercise(M)
Direct
14.5K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
May 28, 2026
Award(A)
Restricted Share Units
Direct
7.2K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Jun 6, 2025
Exercise(M)
Direct
9.6K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Jun 5, 2025
Award(A)
Restricted Share Units
Direct
14.5K shares-

		Type	Shares	Price		Ownership
Aug 21, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	415	$37.25	$15,459	Direct
Jun 5, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	14,492	-	$0	Direct
May 28, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Award(A) Restricted Share Units	7,242	-	-	Direct
Jun 6, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	9,632	-	-	Direct
Jun 5, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Award(A) Restricted Share Units	14,492	-	-	Direct

1-5 of 5 transactions

About Satchi-Fainaro Ronit

Satchi-Fainaro Ronit (SEC CIK 0001742782) files insider reports with the SEC as Director of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).

Signal8 holds 4 ownership filings by Satchi-Fainaro Ronit, all Form 4s, filed between Jun 9, 2025 and Aug 25, 2026. Those filings report 5 transactions, from Jun 5, 2025 to Aug 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Satchi-Fainaro Ronit's filings is in TEL AVIV.

Recent filings by Satchi-Fainaro Ronit

Aug 21, 2026: Open-market sale of TEVA shares (Form 4, code S).
Jun 5, 2026: Option exercise of TEVA shares (Form 4, code M).
May 28, 2026: Grant or award of TEVA derivative securities (Form 4, code A).
Jun 6, 2025: Option exercise of TEVA shares (Form 4, code M).
Jun 5, 2025: Grant or award of TEVA derivative securities (Form 4, code A).

Other insiders filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Bergwerk Dov, Interim Cheif Legal Officer
Savage Brian, Interim Chief Legal Officer
MIGNONE ROBERTO, Director
Weiss Amir, Chief Accounting Officer
Lippman Evan, EVP, Business Development
Zaks Tal Zvi, Director

How to read Form 4 transaction codes